Shares of Insys Therapeutics Inc (NASDAQ:INSY) have received an average recommendation of “Hold” from the seven ratings firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $6.35.
A number of research analysts have weighed in on the stock. ValuEngine upgraded shares of Insys Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, March 1st. Royal Bank of Canada dropped their target price on shares of Insys Therapeutics from $9.00 to $7.00 and set an “outperform” rating on the stock in a research note on Friday, March 8th. Cantor Fitzgerald assumed coverage on shares of Insys Therapeutics in a research note on Tuesday, January 22nd. They issued an “overweight” rating and a $4.40 target price on the stock. Janney Montgomery Scott set a $11.00 target price on shares of Insys Therapeutics and gave the company a “buy” rating in a research note on Saturday, January 19th. Finally, Piper Jaffray Companies set a $4.00 target price on shares of Insys Therapeutics and gave the company a “sell” rating in a research note on Friday, March 8th.
INSY opened at $1.19 on Thursday. The stock has a market capitalization of $72.13 million, a price-to-earnings ratio of -0.86 and a beta of 2.43. Insys Therapeutics has a twelve month low of $0.82 and a twelve month high of $11.65.
Insys Therapeutics (NASDAQ:INSY) last released its earnings results on Friday, May 10th. The specialty pharmaceutical company reported ($0.55) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.33). The company had revenue of $7.63 million during the quarter, compared to analysts’ expectations of $14.95 million. Insys Therapeutics had a negative net margin of 346.61% and a negative return on equity of 1,430.52%. The firm’s revenue was down 68.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.19) earnings per share. As a group, equities research analysts anticipate that Insys Therapeutics will post -1.55 EPS for the current year.
Several hedge funds have recently made changes to their positions in the stock. BlackRock Inc. lifted its stake in shares of Insys Therapeutics by 2.8% during the 3rd quarter. BlackRock Inc. now owns 2,710,787 shares of the specialty pharmaceutical company’s stock valued at $27,325,000 after buying an additional 73,282 shares in the last quarter. Vanguard Group Inc lifted its stake in shares of Insys Therapeutics by 4.7% during the 3rd quarter. Vanguard Group Inc now owns 2,661,324 shares of the specialty pharmaceutical company’s stock valued at $26,825,000 after buying an additional 119,776 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Insys Therapeutics by 4.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,661,324 shares of the specialty pharmaceutical company’s stock valued at $26,825,000 after buying an additional 119,776 shares in the last quarter. ETF Managers Group LLC purchased a new stake in shares of Insys Therapeutics during the 4th quarter valued at approximately $5,076,000. Finally, Norges Bank purchased a new stake in shares of Insys Therapeutics during the 4th quarter valued at approximately $2,195,000. Institutional investors own 13.92% of the company’s stock.
About Insys Therapeutics
Insys Therapeutics, Inc, a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS.
Featured Article: Capital gains and your 401(k) or IRA
Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.